Products
MELNUM
To address the limitations of current treatment options for melanoma arising from tumor heterogeneity. we engineered Melnum.
Melnum utilizes non-viral delivery methods – lipid nanoparticles (LNPs) for targeting melanoma TME and TFAP2.
Advantages with LNP Delivery
Safety
Cost
Precision
When will this be released?
Our research is currently ongoing. We’re aiming for a clinical beta release of our product in 2025. We’ll keep all of you updated through our newsletter.